London, June 10, 2026, 15:51 BST
- Haleon shares last traded at 336.10p/336.20p, ticking up 0.60p, or 0.18%. The FTSE 100 edged higher, up 0.04%.
- Investors are watching Haleon’s £175 million India investment, which targets growth in oral-health manufacturing and rural distribution.
- Haleon picked up 16.6 million shares for cancellation as part of its buyback, according to a June 8 filing, bringing a capital-return element into the shares.
Haleon shares ticked up in London on Wednesday. Investors looked at a new £175 million India expansion and renewed buybacks, balancing that with a share price that had fallen earlier this week. The company, which owns Sensodyne and Advil, changed hands at 336.10p/336.20p, up 0.60p. Shares opened at 338.40p after closing Tuesday at 335.50p.
Haleon edged higher on Wednesday after dropping 1.78% to £3.31 on Monday, lagging the FTSE 100’s 0.05% uptick, data from MarketWatch said. The small move up hints investors are weighing the company’s new emerging-market strategy following a softer period for Haleon shares.
The company said June 8 it plans to spend about £175 million on a new oral-health plant in Madhya Pradesh, central India. The plant is slated to open in early 2028, with supply coming online the year after. It’s supposed to help meet demand in India and other parts of Asia.
Haleon wants investors to pay less attention to weaker demand in some areas and focus on parts of the business where it says it can still raise prices and expand. India is already a top oral-health market for Haleon. The company said India’s consumer health market could top £23 billion by 2030.
Haleon CEO Brian McNamara said India is a “key strategic market” and that the company’s investment could bring Haleon products to over 300 million more consumers in the country. Haleon’s plan aims to roll out cheaper Sensodyne packs, expand rural distribution and target more than three million outlets nationwide by 2030. Haleon Corporate
Haleon is putting money into its top growth area. The company’s first-quarter trading update showed 2.2% organic revenue growth, which factors out currency shifts and transactions to get at the core sales trend. Oral Health jumped 8.3%, with Sensodyne and parodontax leading. Total reported revenue came in at £2.86 billion.
The weak spot is still there. Haleon said a mild cold-and-flu season knocked about 130 basis points off first-quarter growth, or around 1.3 percentage points. Respiratory Health revenue dropped 3.4%. This is why the India deal looks less like a quick fix for earnings and more like a bet on future growth.
Haleon’s latest buyback hands investors fresh short-term support. The company said in a June 8 Form 6-K it bought 16,585,448 ordinary shares for cancellation from June 1 to June 4, with trading on the London Stock Exchange, Cboe UK, and Aquis. The company buyback cuts share count, which can lift earnings per share if profits stay level.
Haleon said once the purchases clear, its registered share capital will stand at 8,842,752,346 ordinary shares, with 12,063,502 held in treasury and 8,830,688,844 carrying voting rights. The filing lets investors track how the £500 million 2026 buyback is flowing into the share count.
Haleon is sticking with its full-year 2026 targets. The group still sees organic revenue moving 3% to 5% higher and adjusted operating profit rising at a high-single-digit rate, at constant currency. Profit growth does not include exchange-rate effects. In its April update, Haleon said it had completed about 36% of the scheduled 2026 buyback by the first quarter.
India may take a while to lift volumes. The new plant is not set to start supplying products before 2029, and reaching rural buyers will depend on how well Haleon executes, local pricing, and whether consumers pick up specialist toothpaste. At the same time, Haleon still needs to show stronger growth in the second half after a patchy cold and flu season and choppy demand. If volumes stay sluggish, buybacks might not ease ongoing questions about organic growth.
Haleon’s half-year numbers are out July 30. Investors want to see if Oral Health growth, a pick-up in the U.S., and more money going into emerging markets can keep the 2026 guidance on track.
